The present invention is a yogurt product that may be consumed by dogs and other mammalian pets. The yogurt product is in an unflavored form comprising as essential constituents: (A) 0% to 88% by weight water; (B) 0.2% to 25% by weight of a no-fat protein component selected from the group consisting of skim milk and cultured skim milk; (C1) 0.001% to 6% by weight sugar component comprising: (C1) 0.001% to 6% polydextrose and (C2) 0.001% to 6% Glycoses and Galactoses; (D) 2% to 8% by weight milk derived solids; (E) 0.2% to 2.5% by weight stabilizers and emulsifiers; and (F) at least one probiotic microorganism. The yogurt product may be refrigerated and served as a mousse, frozen dessert, or as a fermented yogurt drink similar to Ayran or Kefir. A method for producing the yogurt product is also disclosed herein.

The present application relates to a Bifidobacterium breve or progeny thereof. Specifically, the present application relates to Bifidobacterium breve 207-1 and a composition, culture, food product or dietary supplement containing the same. The present application also relates to the use of Bifidobacterium breve 207-1 and the composition, culture, food product or dietary supplement containing the same in medicine.

An object of this present invention is to provide a composition for inhibiting norovirus infection which can inhibit norovirus from infecting a human, and the object is achieved by a composition for inhibiting norovirus infection containing one or more kinds of bacteria selected from the group consisting of Bifidobacterium breve, Bifidobacterium longum subsp. infantis, Bifidobacterium animalis, Bifidobacterium bifidum, Bifidobacterium catenulatum, Lactobacillus gasseri, Lactobacillus helveticus, Lactobacillus delbrueckii subsp. Bulgaricus and Lactobacillus paracasei as an active ingredient.

The invention concerns the use of prebiotics and probiotics for the treatment of infections in allergic patients.

The invention discloses a composition comprising LNT and at least another human milk oligosaccharide or precursor thereof, for use in preventing and/or treating necrotizing enterocolitis in infants and young children.

An activator suitable for immune response in tumor immunotherapy using an immune checkpoint inhibitor. An agent suitable for potentiating an antitumor effect of an immune checkpoint inhibitor, may contain a probiotic and a prebiotic as active ingredients.

The present invention relates to compositions comprising galactooligosaccharides (GOS) and probiotic bacteria obtained by a process comprising the step of growing the bacteria in a medium comprising GOS, such composition having the effect of boosting the synbiotic effect of the probiotic bacteria with the GOS. Health benefits of the probiotic bacteria as obtained by such a fermentation process are also contemplated.

The present invention relates to a novel Bifidobacterium breve IDCC 4401 strain (accession number: KCTC13169BP) and dead cell thereof ID-BBR4401, which are superb in acid tolerance and bile tolerance and have a preventive or therapeutic effect on dyslipidemia. Having not only an excellent effect of reducing a cholesterol level in the body but alto a very high level of acid tolerance and bile tolerance in contrast to previously known B. breve, the novel Bifidobacterium breve MCC 4401 strain (accession number: KCTC13169BP) of the present invention well exhibits the functionality that the strain has in the digestive duct of animals (especially humans), has an excellent growth potential, and provides sustainable and effective functionality of reducing a level of cholesterol in vivo.

The present disclosure relates to a composition for preventing, relieving or treating climacteric symptoms, the composition comprising lactic acid bacteria and prebiotic composition. The lactic acid bacteria of the present disclosure have β-glucosidase activity and a very excellent ability to convert isoflavones into equol compounds, and thus may exhibit estrogenic activity through synergism with the gut microbiota. Therefore, the lactic acid bacteria of the present disclosure may be effectively used for the prevention, relief or treatment of women's climacteric or menopausal symptoms.

Provided is a composition for preventing or ameliorating a functional gastrointestinal disorder whose active ingredient is Bifidobacterium breve MCC1274 (FERM BP-11175). A composition for preventing or ameliorating a functional gastrointestinal disorder in the present technology can prevent or improve constipation or frequent bowel movements, regulate the number of bowel movements, improve stool quality, prevent or improve constipation, prevent or ameliorate bloating, or prevent or improve abdominal discomfort. Disclosed is a composition for preventing or ameliorating a functional gastrointestinal disorder accompanied by anxiety disorder. A composition for preventing or ameliorating a functional gastrointestinal disorder in the present technology can be used in a pharmaceutical composition or in a food or beverage composition.